NCT02282644已完成不适用
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Risk of death according to positive makers
研究概览
简要总结
The recent data suggest that cancer cells at the origin of prostate cancer metastases can be detected in an early stage. Available techniques allow phenotypic analysis of cancer cells in circulating blood (cellsearch) or in marrow hematopoietic (flow cytometry). Pilot study on 180 patients infected by prostate cancer at all stage of disease, show that c-met marker , integrin alpha 2 and 6 expressed in marrow and quantified by flow cytometry were predictor of metastatic progress. In this new study the investigators will analyze antibody panel by cellsearch and flow cytometry on marrow sample of castration-Resistant prostate cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma or prostate
- •Ongoing effective androgen deprivation therapy (testosterone ≤ 50 ng/mL)
- •Castration-Resistant prostate cancer patient : defined as a minimum of 3 rising PSA values assessed and/or radiological progress confirmed by RECIST and PCWG2
- •Patient who signed informed consent
排除标准
- •Severe disorders of coagulation
- •Major skin lesion on iliac crests
- •Allergies in local anesthetics
- •Psychological instability or psychiatric histories
- •Uncertain follow-up and distant residence
- •History of another invasive cancer and hematologic disease
- •Patient deprived of their freedom by court or administrative order
- •Revocation of consent
研究组 & 干预措施
CellSearch
Experimental
干预措施: Bone marrow sampling (Biological)
结局指标
主要结局
Risk of death according to positive makers
时间窗: Two years
次要结局
- Risk of clinical progression according to positive markers.(Two years)
- Risk of biological progression according to positive markers.(Two years)
- Risk of radiological progression according to positive markers.(Two years)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Early Detection of Prostate Cancer by FACSHyperplasiaProstate CancerNCT00524823Ziv Hospital40
招募中
不适用
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese PopulationProstate CancerNCT03893929Chinese University of Hong Kong5,000
Unknown
不适用
Diagnostic Imaging of Bone Metastases in Prostate Cancer PatientsProstate Cancer Metastatic to BoneNCT03134261Herlev Hospital300
已完成
不适用
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT04516161Bayer1,180
撤回
不适用
Investigation of Protein Biomarkers of Prostate CancerProstate CancerNCT00323180University of New Mexico